Macitentan in the treatment of pulmonary arterial hypertension.

Future Cardiology
Rodrigo ZebadúaTomás Pulido

Abstract

Pulmonary arterial hypertension (PAH) is an uncommon but lethal and progressive disease in which prostacyclin, nitric oxide and endothelin-1 pathways are disturbed and contribute to the pathophysiology of this disease. Endothelin receptor antagonists are a class of drugs that have been approved as PAH therapy. Macitentan is a lipophilic, tissue specific, dual receptor antagonist with a higher potency than bosentan and a reduced risk of hepatic injury. Macitentan has shown a reduction in morbidity and mortality due to PAH at long-term follow-up and improvements in hemodynamics, exercise capacity and functional class at the short term. Its main adverse events are nasopharyngitis, bronchitis and an increased risk of anemia. We review the clinical data of macitentan and its use in PAH.

References

Jul 9, 1992·The New England Journal of Medicine·B W ChristmanJ E Loyd
Jan 1, 1989·Journal of Cardiovascular Pharmacology·H KuriharaT Masaki
Jul 1, 1993·Proceedings of the National Academy of Sciences of the United States of America·A M MalekS Izumo
Jun 17, 1993·The New England Journal of Medicine·A GiaidD J Stewart
Oct 1, 1996·Circulation Research·C R BaconA P Davenport
Mar 17, 1999·British Journal of Pharmacology·F D Russell, A P Davenport
Apr 20, 2005·Journal of Cardiovascular Pharmacology·Fernando Rodríguez-PascualSantiago Lamas
Feb 3, 2007·Current Vascular Pharmacology·Ali BouallegueAshok K Srivastava
Mar 28, 2007·Drugs·Lesley J Scott
Sep 11, 2008·The Journal of Pharmacology and Experimental Therapeutics·Marc IglarzMartine Clozel
Sep 8, 2009·The American Journal of Cardiology·Chetan V HampoleSanjiv J Shah
Sep 22, 2009·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Oliver KummerStephan Krähenbühl
May 5, 2011·European Journal of Clinical Pharmacology·Patricia N SidhartaJasper Dingemanse
Mar 31, 2012·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·Shirin BrudererJasper Dingemanse
Apr 7, 2012·Life Sciences·Janet J MaguireAnthony P Davenport
Jan 29, 2013·European Journal of Pharmacology·Johanna WeissWalter Emil Haefeli
May 18, 2013·The European Respiratory Journal·Ganesh RaghuUNKNOWN MUSIC Study Group
Jul 26, 2013·The New England Journal of Medicine·Hossein-Ardeschir GhofraniUNKNOWN PATENT-1 Study Group
Aug 30, 2013·The New England Journal of Medicine·Tomás PulidoUNKNOWN SERAPHIN Investigators
Oct 19, 2013·Pharmacology & Therapeutics·David MontaniMarc Humbert
Jan 25, 2014·The Annals of Pharmacotherapy·Irene S HongLinda M Catanzaro
Dec 3, 2014·European Respiratory Review : an Official Journal of the European Respiratory Society·Marius M Hoeper, J Simon R Gibbs
Dec 3, 2014·European Respiratory Review : an Official Journal of the European Respiratory Society·Hossein-Ardeschir Ghofrani, Marc Humbert
Dec 3, 2014·European Respiratory Review : an Official Journal of the European Respiratory Society·Robert Naeije, Alessandra Manes
Apr 4, 2015·The Canadian Journal of Cardiology·Steeve Provencher, John T Granton
May 13, 2015·Seminars in Nephrology·Janet J Maguire, Anthony P Davenport

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Methods Mentioned

BETA
PCR

Software Mentioned

MUSIC
SERAPHIN
MAESTRO

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.